Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease. Everolimus CAS# 159351-69-6, is the active ingredient for Afinitor®. Click for more information on, and availability of Everolimus. Also, click for more articles on breast cancer and the HER2 receptor. The approval was based on a[…]
FDA Approves Everolimus for Advanced Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, Immunosuppressant Tags: 159351-69-6breast cancerEverolimusmetastatic breast cancerPfizer Jul 20, 2012
Prepare for the Future Exaction of Oncology Products
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6acute lymphoblastic leukemiaBortezomibEverolimusLenalidomideleukemiamultiple myeloma Jul 05, 2012
The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007. Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]
Everolimus shoots two very different birds with one stone; cancer cells and coronary stents
Drug Research & Development API, Immunosuppressant Tags: 159351-69-6Everolimuskinase inhibitor Jun 08, 2011
In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant[…]
Immunosuppressive Drugs for Transplant – Treatments, Side Effects, and Future Research & Development
Drug Research & Development API, Immunological Agent, Immunosuppressant Tags: 159351-69-6191732-72-6EverolimusFingolimod HydrochlorideImmunosuppressantLenalidomideMethotrexateSirolimus Mar 15, 2011
For organ transplant patients, the normally protective immune response can threaten the longevity and function of the transplanted organ. Currently, organ transplant patients must take immunosuppressive or anti-rejection medication to prevent the immune system from fighting against the new, transplanted organ. Often a choice is made between the certain damage of a steroid drug, and[…]
